<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="97269">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01671657</url>
  </required_header>
  <id_info>
    <org_study_id>2012-AUX-008</org_study_id>
    <nct_id>NCT01671657</nct_id>
  </id_info>
  <brief_title>US Eeva™ Pregnancy Investigational Clinical Study (US EPIC)</brief_title>
  <acronym>US EPIC</acronym>
  <official_title>US Eeva™ Pregnancy Investigational Clinical Study (US EPIC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Auxogyn, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Auxogyn, Inc.</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical investigation is to gather data to evaluate the impact of using
      Eeva with traditional morphology grading on implantation rates.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this clinical investigation is to gather data to evaluate the impact of
      implantation rates for Day 3 embryo transfers using Eeva and morphology grading (test group)
      versus Day 3 embryo transfers using morphology grading only (from a concurrent control
      group).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case Control</study_design>
  <primary_outcome>
    <measure>Rate of implantation</measure>
    <time_frame>5-6 gestational age</time_frame>
    <safety_issue>No</safety_issue>
    <description>To compare implantation rates for the Day 3 embryo transfers that used Eeva with morphology grading (test group) versus Day 3 embryo transfers using morphology grading only (control group).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate clinical pregnancy rates from the Eeva Test group to the Control group</measure>
    <time_frame>5-6 weeks gestational age</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ongoing pregnancy rate</measure>
    <time_frame>Gestational age week 8-12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple pregnancy rate</measure>
    <time_frame>Gestational age weeks 5-6 and 8-12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spontaneous miscarriage rate</measure>
    <time_frame>Gestational age week 8-12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>Eeva Test Group</arm_group_label>
    <description>Day 3 embryo transfers that used Eeva with morphology grading (Test Group).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Matched case control group</arm_group_label>
    <description>Day 3 embryo transfers using morphology grading only (from concurrent Control Group).</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients undergoing in vitro fertilization treatment who provide informed consent and plan
        to undergo Day 3 embryo transfer.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women undergoing fresh in vitro fertilization treatment using their own    eggs or
             donor eggs.

          -  IVF cycle attempts ≤ 2.

          -  Egg age ≤ 40 years.

          -  Planned Day 3 embryo transfer.

          -  At least 4 normally fertilized eggs (2PN).

          -  All 2PN embryos must be imaged by Eeva.

          -  Ejaculated sperm or sperm from the epididymis (fresh or frozen).

          -  Willing to comply with study protocol and procedures.

          -  Willing to provide written informed consent.

        Exclusion Criteria:

          -  Planned preimplantation genetic diagnosis or preimplantation genetic screening.

          -  Planned &quot;freeze all&quot; cycle (oocytes or embryos).

          -  Sperm retrieved from testicular tissue.

          -  Abnormal uterine cavity as evaluated by standard methods.

          -  Gestational carrier.

          -  Endometriosis

          -  Hydrosalpinx.

          -  History of cancer.

          -  Concurrent participation in another clinical study.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shehua Shen, MD, ELD</last_name>
    <role>Study Director</role>
    <affiliation>Auxogyn, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Monica Ransom</last_name>
    <phone>650-627-7604</phone>
    <email>mransom@auxogyn.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fertility Physicians of Northern California</name>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <zip>95124</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>G. David Adamson, MD</last_name>
      <email>gdadamson@arcfertility.com</email>
    </contact>
    <contact_backup>
      <last_name>Lourella Palao</last_name>
      <phone>408-355-1727</phone>
      <email>lourellapalao@fpnc.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 11, 2014</lastchanged_date>
  <firstreceived_date>August 21, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>In vitro fertilization</keyword>
  <keyword>Assisted reproductive therapy</keyword>
  <keyword>Time-lapse image recording</keyword>
  <keyword>Image analysis software</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
